IAEA contribution to the development of copper-64 radiopharmaceuticals for theranostic applications.

IAEA contribution to the development of copper-64 radiopharmaceuticals for theranostic applications. Q J Nucl Med Mol Imaging. 2020 Oct 07;: Authors: Jalilian AR, Osso JA, Vera-Araujo J, Kumar V, Harris MJ, Gutfilen B, Guérin B, Li H, Zhuravlev F, Chakravarty R, Alirezapour B, Ávila-Rodríguez MA, Khan IU, Aljammaz I, Assaad T, Luurtsema G, Smith J, Duatti A Abstract Copper-64 is a very attractive radioisotope with unique nuclear properties that allow using it as both a diagnostic and therapeutic agent, thus providing an almost ideal example of a theranostic radionuclide. A characteristic of Cu-64 stems from the intrinsic biological nature of copper ions that play a fundamental role in a large number of cellular processes. Cu-64 is a radionuclide that reflects the natural biochemical pathways of Cu-64 ions, therefore, can be exploited for the detection and therapy of certain malignancies and metabolic diseases. Beside these applications of Cu-64 ions, this radionuclide can be also used for radiolabelling bifunctional chelators carrying a variety of pharmacophores for targeting different biological substrates. These include peptide-based substrates and immunoconjugates as well as small-molecule bioactive moieties. Fueled by the growing interest of Member States (MS) belonging to the International Atomic Energy Agency (IAEA) community, a dedicated Coordinated Research Project (CRP) was initiated in 2016, which recruited thirteen part...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research